Medicine Recommendations

 Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Moderate to severe symptoms of uterine fibroids (NICE TA832)

NICE TA832 - Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

Patients on haemodialysis

To be initiated by renal consultant/SpR and continued in primary care.

Preventing episodes of overt hepatic encephalopathy (NICE TA337)

NICE TA337 - Rifaximin for preventing episodes of overt hepatic encephalopathy

Rifaximin as second line antibacterial treatment for the treatment of Small Intestinal Bacterial Overgrowth

Amyotrophic Lateral Sclerosis form of Motor Neurone Disease (NICE TA20)

NICE TA20 - Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease 

Preventing migraine (NICE TA906)

NICE TA906 - Rimegepant for preventing migraine

Treating migraine (NICE TA919)

NICE TA919 - Rimegepant for treating migraine

Risankizumab for treating moderate to severe plaque psoriasis (NICE TA596)

NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis

Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA803

NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Previously treated moderately to severely active Crohn's disease (NICE TA888)

NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease

Osteoporosis (NICE TA464)

NICE TA464 - Bisphosphonates for treating osteoporosis 

Acute and chronic psychoses, mania; short-term treatment of persistent aggression in patients with moderate to severe Alzheimer's dementia unreponsive to non-pharmacological interventions and where there is a risk of harm to self or others; short-term treatment of persistent aggression in conduct disorder

MHRA Drug Safety Update - Drug name confusion

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

MHRA Drug Safety Update - Drug name confusion

MHRA Drug Safety Update - Risperidone and paliperidone: risk of floppy iris syndrome

Rheumatoid arthritis (LSCMMG pathway)

Autoimmune haemolytic anaemia

Idiopathic thrombocytopenia purpura

Membranous glomerulonephritis

Relapsing steroid sensitive nephrotic syndrome in adults

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and extended prevention of recurrent DVT and PE in adults

NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism